Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonix phase II study of cyclobenzaprine HCl in adults with PTSD in Kenya
PACTR202012739471223Phase 2Not yet recruiting
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing cyclobenzaprine hydrochloride with placebo (2 arms). Primary endpoint: Change from baseline in total CAPS-5 score at landmark visit. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
cyclobenzaprine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on PACTR202012739471223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012739471223.